We serve Chemical Name:2-Vinyloxirane CAS:930-22-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Vinyloxirane
CAS.NO:930-22-3
Synonyms:2-Vinyloxirane;3,4-EPOXY-1-BUTENE;EINECS 213-210-4;Oxirane, 2-ethenyl-;2-ethenyloxirane;MFCD00005149;UNII:478ERR5NKR
Molecular Formula:C4H6O
Molecular Weight:70.090
HS Code:2910900090
Physical and Chemical Properties:
Melting point:-135ºC
Boiling point:70.0±9.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.578
PSA:12.53000
Exact Mass:70.041862
LogP:-0.03
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1993 3/PG 2
Packing Group:II
Contact us for information like 2-Vinyloxirane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,UNII:478ERR5NKR physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00005149 Use and application,EINECS 213-210-4 technical grade,usp/ep/jp grade.
Related News: Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important. 2-Vinyloxirane manufacturer Process: The importance of safety is obvious. The research and development of specialty drug substances (especially high-barrier generic drug substance drugs) usually need to avoid the original process patents, and some chemicals are developed because of the complex structure or the harsh synthetic conditions The synthetic route is more difficult, so the importance of process design capabilities of API companies is becoming more important. 2-Vinyloxirane supplier It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer. 2-Vinyloxirane vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 2-Vinyloxirane factory In August, the Company announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,370,452 covering compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell, including an iPSC.
